Zevra Therapeutics reports Q2 EPS (15c), consensus (34c)

Reports Q2 revenue $8.47M, consensus $3.03M. “The first half of 2023 has been a time of dynamic change for Zevra, and we are pleased with our progress in executing on the key priorities for our programs in Niemann-Pick Disease type C and Idiopathic Hypersomnia,” said Christal Mickle, interim Chief Executive Officer and Chief Development Officer at Zevra. “We have made meaningful progress in our preparation of the arimoclomol NDA, including a productive and collaborative pre-submission meeting with the FDA earlier this month, which provides confidence as we anticipate re-submission of the NDA package by the end of this year. In addition, the KP1077 program is on track, and we are pleased with progress toward the AZSTARYS net sales milestones and the momentum toward the possibility of earning a second net sales milestone in 2023. Zevra has several upcoming catalysts for value creation, and we believe our focus on developing and commercializing therapies for rare diseases with a patients-first approach will lead to better therapies for the communities we serve.”